Diamyd Medical develops combination therapies for the treatment of autoimmune diabetes with the objective of preventing, delaying or stopping the autoimmune attack on beta cells by inducing tolerance to GAD, one of the major autoantigens in autoimmune diabetes and thus preserve the body's own ability to produce insulin.
By combining various substances with different mechanisms of actions, e.g.